Influence of intracerebral administration of NO agents in dorsal hippocampus (CA1) on cannabinoid state-dependent memory in the step-down passive avoidance test.
In the present study, the effects of nitric oxide agents on WIN55, 212-2 induced state-dependent memory of passive avoidance task were examined in mice. One-trial step-down paradigm was used for the assessment of memory retention in adult male NMRI mice. Post-training intra-CA1 administration of CB1 and CB2 receptor agonists, WIN55, 212-2 (0.25, 0.5 and 1 microg/mouse), dose-dependently decreased memory retrieval. The memory impairment induced by post-training administration of WIN55, 212-2 (1 microg/mouse) was restored by pre-test administration of the same dose of the drug (1 microg/mouse, intra-CA1), showing the WIN55, 212-2 state-dependent memory. Single intra-CA1 administration of L-arginine (0.3, 1 and 3 microg/mouse) or L-NAME (0.3, 1 and 3 microg/mouse), 5 min pre-test could not alter memory retrieval. On the other hand, in the animals in which retrieval was impaired due to post-training administration of WIN55, 212-2 (1 microg/mouse), pre-test intra-CA1 administration of l-arginine (1 and 3 microg/mouse), but not L-NAME (0.3, 1 and 3 microg/mouse) 24h after training restored memory retrieval. Also, in the animals which received both post-training (1 microg/mouse) and pre-test injections of WIN55, 212-2 (1 microg/mouse), the injection of L-NAME (3 microg/mouse, intra-CA1), 2 min before pre-test administration decreased retrieval. Furthermore, in the animals under the influence of post-training administration of WIN55, 212-2 (1 microg/mouse), pre-test co-administration of non-effective doses of WIN55, 212-2 (0.25 microg/mouse) and L-arginine (0.3 and 1 microg/mouse), increased the restoration of memory by pre-test WIN55, 212-2. These findings may demonstrate the involvement of NO in state-dependent memory induced by intra-CA1 administration of WIN55, 212-2.
Department of Biology, Faculty of Basic Sciences, Azad University, Garmsar branch, Semnan, Iran.
Mohammad
M
Nasehi
Morteza
M
Piri
Nida
N
Jamali-Raeufy
Mohammad Reza
MR
Zarrindast
D000818:Animals; D001120:Arginine / Q000008:administration & dosage; D001362:Avoidance Learning / Q000187:drug effects*; D048588:Benzoxazines / Q000008:administration & dosage*; D056547:CA1 Region, Hippocampal / Q000187:drug effects*; D002186:Cannabinoids / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005106:Exploratory Behavior / Q000187:drug effects; D007276:Injections, Intraventricular; D008297:Male; D008568:Memory / Q000187:drug effects*; D008569:Memory Disorders / Q000139:chemically induced / Q000469:parasitology; D051379:Mice; D008815:Mice, Inbred Strains; D009025:Morpholines / Q000008:administration & dosage*; D019331:NG-Nitroarginine Methyl Ester / Q000008:administration & dosage; D009281:Naphthalenes / Q000008:administration & dosage*; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists
D048588:Benzoxazines; D002186:Cannabinoids; D004791:Enzyme Inhibitors; D009025:Morpholines; D009281:Naphthalenes; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D001120:Arginine; D019331:NG-Nitroarginine Methyl Ester